Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-54P is classified as a pseudogene annotated for RNA, U4 small nuclear 54. Pseudogenes do not produce functional proteins or functional RNA and lack known biological functions, molecular interactions, or disease associations. There is no evidence that RNU4-54P serves as a receptor, drug target, biomarker, or has clinical relevance. Most small nuclear RNA pseudogenes are non-functional genetic elements that arise by duplication or retrotransposition and are not therapeutically actionable. The U4 small nuclear RNA family is crucial for spliceosome function in its canonical genes (e.g., RNU4-2, not RNU4-54P). There is no evidence from sequencing or clinical databases for biological or disease relevance of RNU4-54P; major studies focus on RNU4-2 and other functional snRNA genes. The vast majority of snRNA pseudogenes, including RNU4-54P, are considered non-functional without any protein or RNA product. Published literature and gene databases (GeneCards, NCBI) do not describe therapeutic drug interactions, target roles, biomarker status, or links to pathology for RNU4-54P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 54, pseudogene (RNU4-54P).